Digest Network Come funziona
Network
/
Società
Vi
Non verificato

Viridian Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOtticaSalute

50 comunicati stampa

Guarda tutti i comunicati
26/06/2026
Web e Social Network
Telefonia e Varie
Industria
Biotecnologia
Igiene alimentare
Salute
Ottica
Medicina - Varie
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Eventi
Web e Social Network
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Mercato azionario
Titoli e azioni
Associazioni/Professionisti
Salute
Finanza
Farmaceutica
Ottica
Biotecnologia
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Web e Social Network
Eventi
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Industria
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/03/2026
Web e Social Network
Telefonia e Varie
Industria
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
26/02/2026
Web e Social Network
Finanza
Eventi
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Salute
Scienza
Medicina - Varie
Farmaceutica
Biotecnologia
Mercato azionario
Finanza
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Viridian Therapeutics Prepares for Transformational 2026
Fonte
Viridian Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0